LTX 315

Drug Profile

LTX 315

Alternative Names: LTX-315; Oncopore

Latest Information Update: 14 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lytix Biopharma
  • Class Adjuvants; Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Cell membrane structure modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Soft tissue sarcoma
  • Phase I/II Breast cancer; Malignant melanoma; Solid tumours
  • No development reported Carcinoma

Most Recent Events

  • 14 Jun 2018 Updated efficacy, adverse events and immunogenicity data from a phase I trial in Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2108)
  • 23 Apr 2018 Lytix Biopharma plans a phase II trial for Breast cancer and Malignant melanoma (in combination with checkpoint inhibitor) in first half of 2018 (Lytix Biopharma pipeline, April 2018)
  • 23 Apr 2018 Lytix Biopharma plans a phase II trial for Head and neck cancer (Neoadjuvant therapy) in first half of 2018 (Lytix Biopharma pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top